ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
uniQure NV

uniQure NV (QURE)

13.85
-2.07
(-13.00%)
Closed January 11 4:00PM
14.00
0.15
(1.08%)
After Hours: 5:52PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
14.00
Bid
13.88
Ask
14.10
Volume
1,983,275
13.80 Day's Range 16.0357
3.73 52 Week Range 19.18
Market Cap
Previous Close
15.92
Open
15.83
Last Trade
50
@
13.9982
Last Trade Time
Financial Volume
$ 29,055,518
VWAP
14.6503
Average Volume (3m)
2,244,594
Shares Outstanding
48,743,140
Dividend Yield
-
PE Ratio
-2.19
Earnings Per Share (EPS)
-6.33
Revenue
21.9M
Net Profit
-308.48M

About uniQure NV

uniQure NV is a gene therapy company. It develops treatment and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipel... uniQure NV is a gene therapy company. It develops treatment and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Amsterdam, North Holland, Nld
Founded
-
uniQure NV is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker QURE. The last closing price for uniQure NV was $15.92. Over the last year, uniQure NV shares have traded in a share price range of $ 3.73 to $ 19.18.

uniQure NV currently has 48,743,140 shares outstanding. The market capitalization of uniQure NV is $775.99 million. uniQure NV has a price to earnings ratio (PE ratio) of -2.19.

uniQure NV (QURE) Options Flow Summary

Overall Flow

Bullish

Net Premium

480k

Calls / Puts

400.00%

Buys / Sells

150.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

QURE Latest News

uniQure Announces Pricing of its Public Offering

LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...

uniQure Announces Proposed Public Offering

LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-3.55-20.227920227917.5519.1813.85160457216.86111193CS
4-0.98-6.5420560747714.9819.1813.85158308416.82859548CS
127.72122.9299363066.2819.185.35224459413.61107324CS
267.35110.5263157896.6519.184.45207604611.00952262CS
527.38111.4803625386.6219.183.7316634869.10278229CS
156-5.39-27.79783393519.3928.2553.73107366811.78194387CS
260-60.22-81.137159795274.2276.68693.7384292618.49194424CS

QURE - Frequently Asked Questions (FAQ)

What is the current uniQure NV share price?
The current share price of uniQure NV is $ 14.00
How many uniQure NV shares are in issue?
uniQure NV has 48,743,140 shares in issue
What is the market cap of uniQure NV?
The market capitalisation of uniQure NV is USD 775.99M
What is the 1 year trading range for uniQure NV share price?
uniQure NV has traded in the range of $ 3.73 to $ 19.18 during the past year
What is the PE ratio of uniQure NV?
The price to earnings ratio of uniQure NV is -2.19
What is the cash to sales ratio of uniQure NV?
The cash to sales ratio of uniQure NV is 30.83
What is the reporting currency for uniQure NV?
uniQure NV reports financial results in USD
What is the latest annual turnover for uniQure NV?
The latest annual turnover of uniQure NV is USD 21.9M
What is the latest annual profit for uniQure NV?
The latest annual profit of uniQure NV is USD -308.48M
What is the registered address of uniQure NV?
The registered address for uniQure NV is PAASHEUVELWEG 25A, AMSTERDAM, NORTH HOLLAND, 1105 BP
What is the uniQure NV website address?
The website address for uniQure NV is www.uniqure.com
Which industry sector does uniQure NV operate in?
uniQure NV operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VRMEVerifyMe Inc
$ 2.57
(52.98%)
57.7M
WKEYWISeKey International Holdings AG
$ 10.041
(52.83%)
6.69M
DATSDatChat Inc
$ 4.8105
(49.86%)
158.56M
CDTConduit Pharmaceuticals Inc
$ 0.1214
(48.05%)
1.16B
INTZIntrusion Inc
$ 2.8888
(44.44%)
40.45M
IGMSIGM Biosciences Inc
$ 2.095
(-66.21%)
5.81M
CDTGCDT Environmental Technology Investment Holdings Ltd
$ 1.87
(-51.30%)
2.28M
MODVModivCare Inc
$ 6.51
(-47.88%)
2.73M
AIFUAIX Inc
$ 0.420501
(-47.76%)
7.85M
MRSNMersana Therapeutics Inc
$ 0.691
(-46.85%)
58.44M
CDTConduit Pharmaceuticals Inc
$ 0.1214
(48.05%)
1.17B
NVDANVIDIA Corporation
$ 135.91
(-3.00%)
207.53M
RGTIRigetti Computing Inc
$ 8.9299
(-11.06%)
178.82M
VMARVision Marine Technologies Inc
$ 2.14
(40.79%)
175.57M
DATSDatChat Inc
$ 4.8105
(49.86%)
158.65M

QURE Discussion

View Posts
PonkenPlonken PonkenPlonken 3 weeks ago
dont like throwing the term around but this has buyout written all over
super strong up here

Novartis for AMT-130 Huntington program?
πŸ‘οΈ0
tw0122 tw0122 1 month ago
$15.72 + 113% time to exit all hard time breaking $15.78 resistance which would have led to $17s
πŸ‘οΈ0
tw0122 tw0122 1 month ago
$15.35 + 103%
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
rock n roll
πŸ‘οΈ0
tw0122 tw0122 1 month ago
$13.71 + 88%
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
Never before data and 11$ in cash held back by ex stock broker CEO Matt Kapusta. Is too busy milking shareholders vs advancing trials.
but dont worry, he wont make it go kaput.
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
Never before data and 11$ in cash held back by ex stock broker CEO Matt Kapusta. Is too busy milking shareholders vs advancing trials.
but dont worry, he wont make it go kaput.
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 3 months ago
turnaround in the making
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 3 months ago
Here it comes
Still 11$ in cash and super science. Held back by blood leech Ex-Wallstreet CEO... BP wont care
πŸ‘οΈ0
Biggiee Biggiee 3 months ago
Get in or don’t. It’s time
$QURE
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 4 months ago
Everyone forgot about this as they are much to busy chasing the next ultra risky 10% flip.
SOOO undervalued. Suppressed by bored traders and gamblers leaving.
The data will speak again and people will realize this is worth 2-4bn.
πŸ‘οΈ0
tbonaces80 tbonaces80 6 months ago
Buying for swing. Tier 1
πŸ‘οΈ0
retireat40 retireat40 6 months ago
Agree until more news is released.
πŸ‘οΈ0
Romiman Romiman 6 months ago
Got in at 5.85, I’ll be out tomorrow, this one is done.
πŸ‘οΈ0
retireat40 retireat40 6 months ago
WTH? New LOD every time I check.
πŸ‘οΈ0
retireat40 retireat40 6 months ago
Nope
πŸ‘οΈ0
retireat40 retireat40 6 months ago
Turd city…
πŸ‘οΈ0
retireat40 retireat40 6 months ago
Even less volume today than last Friday.
πŸ‘οΈ0
retireat40 retireat40 6 months ago
Agree. Odd that it trades in the 8’s
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 6 months ago
I became an investor the second i saw the results but i also traded around my position. Ergo I am riding a free ticket now.
Company has 11$ per share in cash and the science is probably worth 2-4bn $.
πŸ‘οΈ0
retireat40 retireat40 6 months ago
Bull or bear?
πŸ‘οΈ0
retireat40 retireat40 6 months ago
Looked like crapola today
πŸ‘οΈ0
tbonaces80 tbonaces80 6 months ago
Flagg forming
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 6 months ago
institutions use liquidity = take a seat and watch the scenario unfold.
πŸ‘οΈ0
retireat40 retireat40 6 months ago
We’ll see. 80% drop in volume today.
πŸ‘οΈ0
TechandBio TechandBio 6 months ago
UniQure Interesting move here solid pipeline added a few calls for early July for fun.
Keep an eye o Ice Cure killing cancer by cryoblation ICCM one of the most undervalued stocks.
$QURE
πŸ‘οΈ0
tbonaces80 tbonaces80 6 months ago
Great chart. Shooting for a rip beteen $12.41-$16.75.
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 6 months ago
traders are too busy trying to make $ in silly names. Every few months there is a play like this.... that doesnt require much thinking-- only spotting it and letting the big guys do the lifting.
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 6 months ago
Listen to Victor Sung on the recent call. You dont need to be in the know to hear he hasnt seen anything similar

https://edge.media-server.com/mmc/p/m4opdukf
πŸ‘οΈ0
Monksdream Monksdream 8 months ago
QURE under $5
πŸ‘οΈ0
Liam859 Liam859 10 months ago
$QURE $5.14 buy it up
πŸ‘οΈ0
MiamiGent MiamiGent 2 years ago
QURE

$26.36 +3.36 (+14.61%)
As of Nov-23-20224:00:00 PM ET

https://stockcharts.com/h-sc/ui?s=QURE

FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults
BENZINGA 8:12 AM ET Nov-23-2022

UniQure N.V.'s (NASDAQ:QURE) partner CSL Limited (OTC:CSLLY) has received FDA approval for Hemgenix (etranacogene dezaparvovec-drlb), a one-time gene therapy for hemophilia B.
CSL licensed the exclusive global rights to Hemgenix from uniQure in May 2021.
UniQure has received about $500 million so far from CSL and will also be eligible to get up to an additional $1.5 billion in commercial milestone payments and royalties.
Cowen analyst Joseph Thome said that Hemgenix's price of $3.5 million is higher than the brokerage's estimated $1.9 million, but its consultants have been optimistic about the therapy's uptake, Reuters reported.
Results from the pivotal HOPE-B trial support the FDA approval, the largest gene therapy trial in hemophilia B.
Results from the study demonstrated that Hemgenix allowed patients to produce mean factor IX activity of 39% at six months and 36.7% at 24 months post-infusion.
Seven to 18 months post-infusion, the mean adjusted annualized bleeding rate (ABR) for all bleeds was reduced by 54% compared to the six-month lead-in period on factor IX prophylactic replacement therapy (4.1 to 1.9).
In addition, 94% of patients treated with Hemgenix discontinued prophylaxis and remained free of previous continuous routine prophylaxis therapy.
The FDA has already cleared two gene therapies, Zynteglo and Skysona, from Bluebird bio Inc (NASDAQ: BLUE) in August and September, respectively.
πŸ‘οΈ0
Glider549 Glider549 3 years ago
Whoops!
πŸ‘οΈ0
ralphey ralphey 3 years ago
Insiders selling big time while biopharmcatalyst site tries to pump - noit a good sign
πŸ‘οΈ0
Sunnycupid Sunnycupid 7 years ago
Profit taking time .. Good time to short this .. I want to be in for a short
πŸ‘οΈ0
Thoro Thoro 7 years ago
QURE $9.15 high today, nice.
πŸ‘οΈ0
Thoro Thoro 7 years ago
This thing is pretty volatile lately.
πŸ‘οΈ0
Thoro Thoro 7 years ago
QURE Looked great hitting $9.00 today
πŸ‘οΈ0
Thoro Thoro 7 years ago
QURE General Information

http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=QURE.O
πŸ‘οΈ0
Thoro Thoro 7 years ago
Uniqure NV (QURE) Money Flow Index Nearing Key Level

http://tuckermantimes.com/uniqure-nv-qure-money-flow-index-nearing-key-level/247578/

πŸ‘οΈ0
Thoro Thoro 7 years ago
Erratic Trading Showing Unusual Volume in Shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) and uniQure N.V. (NASDAQ:QURE)

https://www.concordregister.com/erratic-trading-showing-unusual-volume-in-shares-of-concert-pharmaceuticals-inc-nasdaqcnce-and-uniqure-n-v-nasdaqqure/

πŸ‘οΈ0
Thoro Thoro 7 years ago
uniQure N.V. NASDAQ:QURE Sees High Volatility in Session

https://aikenadvocate.com/uniqure-n-v-nasdaqqure-sees-high-volatility-in-session/290264/
πŸ‘οΈ0
Thoro Thoro 7 years ago
uniQure N.V. (QURE) PT Set at $13.00 by Chardan Capital

https://weekherald.com/2017/07/24/uniqure-n-v-qure-pt-set-at-13-00-by-chardan-capital.html
πŸ‘οΈ0
Rogerthat1 Rogerthat1 7 years ago
This dog has always been a turd. Why did it run last couple days? Already see signs of rollover on today's intraday imo. $QURE
πŸ‘οΈ0
Dutchdaan Dutchdaan 8 years ago
buying here
πŸ‘οΈ0
Panzer Panzer 8 years ago
Lost all patience in this pos
πŸ‘οΈ0
redsox17 redsox17 8 years ago
Patient is a virtue.
If you know what you are doing it pays off.
πŸ‘οΈ0
jaytea jaytea 8 years ago
That's why it's down another 3%
πŸ‘οΈ0
redsox17 redsox17 8 years ago
Trust me they are. They just don't want you to think that way.
πŸ‘οΈ0
jaytea jaytea 8 years ago
The market does not seem to be overly impressed.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock